Business

Theravance, Inc, which spun off from Theravance Biopharma in 2013, will now be known as "Innoviva" and will trade on NASDAQ under the symbol "INVA," the company said. Innoviva is partnered with GSK on the Relvar/Breo Ellipta fluticasone furoate/vilanterol DPI, the Anoro Ellipta umeclidinium/vilanterol DPI, and a vilanterol monotherapy DPI in development. Innoviva … [Read more...] about Theravance, Inc changes its name to Innoviva

Sanofi will return development and commercialization rights for Afrezza inhaled insulin to MannKind after disapponting sales, and MannKind says that it is considering strategic options for the product. Afrezza was approved by the FDA in June 2014. According to MannKind, The parties will promptly commence transition discussions in order to effect a smooth and … [Read more...] about Sanofi to return Afrezza rights to MannKind

Skyepharma has announced a partnership agreement with Mundipharma for global development and commercialization of Skyepharma's SKP-2076 ICS/LABA/LAMA fixed dose combination MDI. Mundipharma, which already markets Skyepharma's Flutiform fluticasone propionate/formoterol fumarate MDI in Europe and a number of other markets, will pay a non-refundable option fee in the … [Read more...] about Skyepharma partners with Mundipharma on triple combination MDI

GlaxoSmithKline has recalled two lots of Ventolin HFA metered dose inhalers totaling 128,704 inhalers, according to an FDA enforcement report. The company initiated the voluntary recall on December 3, 2015 due to concerns about insufficient propellant in the cans for delivery of all 200 doses. According to a copy of the recall letter posted by a distributor, the … [Read more...] about GSK recalls almost 129,000 Ventolin inhalers

AstraZeneca has announced that it will acquire Takeda's respiratory line for $575 million. According to the company, about 200 Takeda employees will transfer to AstraZeneca as part of the deal. The company is citing the acquisition of roflumilast (Daliresp/Daxas), an oral PDE4 inhibitor for the treatment of COPD, as a highlight of the deal, but it is also … [Read more...] about AstraZeneca to acquire Takeda’s respiratory business

Turing Pharmaceuticals CEO Martin Shkreli has been arrested by the Federal Bureau of Investigations for securities fraud involving illegal stock transactions when he was CEO of Retrophin Pharmaceuticals. Retrophin fired Shkreli in September 2014 and later divested its intranasal oxytocin and ketamine products to his new company, Turing. Retrophin has since sued … [Read more...] about Turing Pharmaceuticals CEO Martin Shkreli arrested for securities fraud

Teva has acquired exclusive marketing and commercialization rights to Egalet Corporation's Sprix ketorolac tromethamine nasal spray in Israel, Gaza and the West Bank, Egalet has announced. Sprix nasal spray is used for the short-term treatment of moderate-to-severe pain in adults. Financial terms were undisclosed but include an upfront payment, sales-based milestone … [Read more...] about Teva to market Sprix nasal spray in Israel

RODES, Inc. and Ligand Pharmaceuticals have announced global license and supply agreements for three products in development using Ligand's Captisol formulation technology, including intranasal budesonide/azelastine for the treatment of allergic rhinitis. RODES will pay all development and commercial costs, make milestone payments, and pay royalties of 8% - 11% on … [Read more...] about RODES Inc licenses Captisol-enabled intranasal budesonide/azelastine from Ligand